2025年8月, 實地研究
The summer has brought more clarity on the specifics of trade and fiscal policy under President Donald Trump. Now investors must weigh the implications for inflation, the economy, and monetary policy.
Delays and rollbacks to the extreme “reciprocal tariffs” unveiled at the start of April—as well as trade agreements with key partners—have helped to anchor market expectations for the effective U.S. tariff rate. But the potential for tariffs targeting certain industries is a source of uncertainty.
The effective tariff rate for the U.S. is likely to end up somewhere between 10% and 20%—compared with roughly 2.5% at the start of 2025. Higher import duties and shifting supply chains should result in higher costs for companies, some of which will be passed through to customers via price increases.
What could this mean for the economy and markets? Inflation could accelerate, consumer spending could fall, and corporate profit margins could be squeezed. Small businesses, which account for more than 70% of U.S. employment, tend to have less pricing power and more sensitivity to the economy and interest rates. As such, they may face more pressure to lay off employees.
On the other hand, the tax and spending legislation that Congress passed in July should be modestly stimulative over the next few years. Here, the question is the extent to which more favorable tax treatment of capital expenditures and research and development will spur business investment. That said, stepped‑up spending on plants and equipment could lead to inflation in input costs.
The Federal Reserve must tread carefully as it walks the tightrope between keeping inflation in check with higher interest rates while being mindful of economic growth. Policymakers must also contend with political pressure to lower rates.
In this dynamic environment, a top-down understanding of the interplay between government policy, the economy, and the outlook for different asset classes can be especially powerful when it’s combined with deep insights into industries and individual companies in the U.S. and beyond.
The following table highlights some of the key policy areas we’re watching and the possible implications for asset allocation.
What we're watching
Potential implications
What we're watching
Potential implications
What we're watching
Potential implications
What we're watching
Potential implications
What we're watching
Potential implications
What we're watching
Potential implications
1 Duration measures a bond’s sensitivity to changes in interest rates.
2 Gil Fortgang, an associate analyst who covers Washington and regulatory policy for T. Rowe Price Investment Management, explored this topic at length in “How the U.S. Election Could Impact the Financials Sector.”
Risks
Fixed‑income securities are subject to credit risk, liquidity risk, call risk, and interest‑rate risk. As interest rates rise, bond prices generally fall. Small‑cap stocks have generally been more volatile in price than the large‑cap stocks. Because of the cyclical nature of natural resource companies, their stock prices and rates of earnings growth may follow an irregular path. While U.S. government‑backed securities generally are considered to be among the highest credit quality, they are subject to market risk. The primary source of risk is the possibility of rising interest rates, which generally cause bond prices to fall. In periods of no or low inflation, other types of bonds, such as US Treasury bonds, may perform better than Treasury Inflation‑Protected Securities. Financial services companies may be hurt when interest rates rise sharply and may be vulnerable to rapidly rising inflation. International investments can be riskier than U.S. investments due to the adverse effects of currency exchange rates, differences in market structure and liquidity, as well as specific country, regional, and economic developments. These risks are generally greater for investments in emerging markets. The value approach to investing carries the risk that the market will not recognize a security’s intrinsic value for a long time or that a stock judged to be undervalued may actually be appropriately priced. Health sciences firms are often dependent on government funding and regulation and are vulnerable to product liability lawsuits and competition from low‑cost generic product. All charts and tables are shown for illustrative purposes only.
Additional Disclosure
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Important Information
Where securities are mentioned, the specific securities identified and described are for informational purposes only and do not represent recommendations.
This material is being furnished for general informational purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. Investment involves risks. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.
The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.
Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources’ accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price
The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.
Hong Kong—Issued by T. Rowe Price Hong Kong Limited, 6/F, Chater House, 8 Connaught Road Central, Hong Kong. T. Rowe Price Hong Kong Limited is licensed and regulated by the Securities & Futures Commission (“SFC”). This material has not been reviewed by the SFC.
Singapore—Issued by T. Rowe Price Singapore Private Ltd. (UEN 201021137E), 501 Orchard Road, #10-02 Wheelock Place, Singapore 238880. T. Rowe Price Singapore Private Ltd. is licensed and regulated by the Monetary Authority of Singapore. This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.
© 2025 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, the Bighorn Sheep design and related indicators (www.troweprice.com/en/intellectual-property) are trademarks of T. Rowe Price Group, Inc. All other trademarks are the property of their respective owners.